Questcor: A Cheap Biotech Stock

Questcor: One-Drug Wonder

Questcor is a rare growth biotech, says Mad Money's Cramer, with a spectacular 42% growth rate, selling at 23 times earnings. Discussing the company's outlook, with Donald Bailey, Questcor Pharmaceuticals, Inc. CEO.

Questcor Pharmaceuticals is a rapidly growing biotech company with a terrific niche business, Cramer said Thursday.

“Questcor’s most recent quarter was spectacular, causing the stock to pop 20 percent on the news,” he said. “Even though the stock has run, it’s still cheap here on a growth basis, selling for 23 times earnings with a spectacular 42 percent growth rate.”

The company’s main product is an autoimmune drug chemical called Acthar Gel, but most of its sales come from combating three main diseases: multiple sclerosis relapses, infantile spasms and various kidney disorders.

To learn more about the company and where it’s headed, Cramer spoke with Questcor’s President and CEO Don Bailey. Watch the video to see the full interview.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? [e-mail]

Questions, comments, suggestions for the Mad Money website? [e-mail]